

Beta-Blocker Heart Attack Trial (BHAT) Publications

Bell RL, Curb JD, Friedman LM, Payne GH. Termination of clinical trials: The Beta-Blocker Heart Attack Trial and the Hypertension Detection and Follow-up Program experience. *Control Clin Trials* 1985;6:102-111.

Bell RL, Curb JD, Friedman LM, McIntyre KM, Payton-Ross C, and the BHAT Research Group. Enhancement of visit adherence in the national Beta-Blocker Heart Attack Trial. *Control Clin Trials* 1985;6:89-101.

Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. *JAMA* 1983;250:2814-2819.

Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. *JAMA* 1982;247:1707-1714.

Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial: design features. *Control Clin Trials* 1981;2:275-285.

Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. *JAMA* 1981;246:2073-2074.

Byington RP, Curb JD, Mattson ME, for the Beta-Blocker Heart Attack Trial Research Group. Assessment of double-blindness at the conclusion of the Beta-Blocker Heart Attack Trial. *JAMA* 1985;253:1733-1736.

Byington RP and Goldstein S, for the BHAT Research Group. The association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta -Blocker Heart Attack Trial. *J Am Coll Cardiol* 1985;6:976-982.

Byington RP, for the Beta -Blocker Heart Attack Trial Research Group. Beta-Blocker Heart Attack Trial: design, methods and baseline results. *Control Clin Trials* 1984;5:382-437.

Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. *Circulation* 1986;73:503-510.

Chiang YK, Hardy RJ, Hawkins CM, Kapadia AS. An illness-death process with time-dependent covariates. *Biometrics* 1989;45:669-681.

DeMets DL, Hardy RJ, Friedman LM, Lan KKG: Statistical aspects of early termination in the Beta-Blocker Heart Attack Trial. *Control Clin Trials* 1984;5:362-372.

Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E, for the Beta-Blocker Heart Attack Trial Research Group: Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. *J Am Coll Cardiol* 1986;7:1-8.

Friedman LM, Byington RP and the Beta-Blocker Heart Attack Trial Research Group. Assessment of angina pectoris after myocardial infarction: comparison of "Rose Questionnaire" with physician judgment in the Beta-Blocker Heart Attack Trial. *Am J Epidemiol* 1985;121:555-562.

Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction patients with mechanical or electrical complications. *Circulation* 1984;69:761-765.

Furberg CD, Byington RP, for the Beta-Blocker Heart Attack Trial Research Group. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. *Circulation* 1983;67(Suppl 1):98-101.

Goldstein S, for the BHAT Research Group: Propranolol therapy in patients with acute myocardial infarction: The Beta-Blocker Heart Attack Trial. *Circulation* 1983;67(Suppl 1):53-57.

Green D, Rossi EC, Haring O. The Beta-Blocker Heart Attack Trial: studies of platelets and Factor VIII. *Thromb Res* 1982;28:261-267.

Hawkins CM, Richardson DW, Vokonas PS, for the Beta-Blocker Heart Attack Trial Research Group: Effect of propranolol in reducing mortality in older myocardial infarction patients--The Beta-Blocker Heart Attack Trial experience. *Circulation* 1983;67(Suppl 1):94-97.

Haywood LJ, for the BHAT Research Group. Coronary heart disease mortality/morbidity and risk in blacks. 1. Clinical manifestation and diagnostic criteria: the experience of the Beta-Blocker Heart Attack Trial. *Am Heart J* 1984;108:787-793.

Howard JM, DeMets D, and The BHAT Research Group: How informed is informed consent? *Control Clin Trials* 1981;2:287-303.

Lichstein E, Morganroth J, Harrist R, Hubble E, for the BHAT Study Group. Effect of propranolol on ventricular arrhythmia: The Beta-Blocker Heart Attack Trial experience. *Circulation* 1983;67(Suppl 1):5-10.

Mattson ME, Curb JD, McArdle R and the AMIS and BHAT Research Groups. Participation in a clinical trial: the patients' point of view. *Control Clin Trials* 1985;6:156-167.

Morganroth J, Lichstein E, Byington RP, for the BHAT Study Group. Beta-Blocker Heart Attack Trial: impact of propranolol therapy on ventricular arrhythmia. *Prev Med* 1985;14:346-357.

Peters RW, Byington R, Arensberg D, Friedman L, Romhilt DW, Barker A, Laubach C, Wilner GW, Goldstein S, for the BHAT Research Group. Mortality in the Beta-Blocker Heart Attack Trial: the circumstances surrounding death. *J Chronic Dis* 1987;40:75-82.

Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial influences on mortality after myocardial infarction. *N Engl J Med* 1984;311:552-559.

Shulman RS, Herbert PN, Capone RJ, McClure D, Hawkins CM, Henderson LO, Saritelli A, Campbell J. Effects of propranolol on blood lipids and lipoproteins in myocardial infarction. *Circulation* 1983;67(Suppl 1):19-21.

Walle T, Byington RP, Furberg CD, McIntyre K, Vokonas P. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. *J Clin Pharm Ther* 1985;38:509-518.